The logic behind the experiment begins with mesenchymal stem cells, or MSCs, which are adult stem cells typically harvested from bone marrow. MSCs naturally shed extracellular vesicles, including microvesicles, which are spherical packets of membrane that carry proteins, lipids, and genetic cargo from the parent cell. Because these vesicles can fuse with recipient cells and deliver their contents, they have attracted intense interest as natural drug delivery vehicles. Unlike living cell therapies, vesicle-based approaches avoid the risks of uncontrolled cell division, immune rejection, and tumor initiation that have complicated stem cell transplantation. The catch is that naive MSC vesicles are not inherently toxic to cancer cells, and in some contexts MSCs have even been reported to support tumor growth. The researchers therefore set out to precondition the stem cells so that their vesicles would inherit a pro-apoptotic payload.

The preconditioning agent was plantaricin, a bacteriocin, meaning a small antimicrobial peptide produced by lactic acid bacteria such as Lactobacillus plantarum. Bacteriocins have long been valued as natural food preservatives, but a growing body of literature suggests some of them carry anticancer activity. Previous work has shown that plantaricin BM-1 reduces the viability of SW480 colorectal cancer cells by inducing caspase-dependent apoptosis, and related bacteriocins such as nisin have been shown to suppress metastatic gene expression in colon cancer cell lines. In the new study, the team exposed human bone marrow-derived MSCs to a sub-lethal dose of plantaricin, specifically 10 micrograms per milliliter, a concentration deliberately kept below the level that harms half of the cells. The idea was to stress the stem cells gently enough that they would package stress signals and apoptotic triggers into the vesicles they released, without damaging the cells themselves.

Harvesting the vesicles required differential ultracentrifugation, a technique that spins conditioned culture media at progressively higher speeds to pellet particles by size and density. The team then characterized the resulting microvesicles using three complementary methods. Flow cytometry confirmed the presence of canonical vesicle surface markers CD9, CD63, and CD81, the molecular calling cards recognized by the International Society for Extracellular Vesicles. Dynamic light scattering measured particle size distributions in suspension, and protein quantification assessed cargo concentration. The comparison between naive and plantaricin-preconditioned vesicles revealed striking physical differences. Vesicles from preconditioned cells were substantially smaller, with a mean diameter of 253 nanometers compared with 618 nanometers for naive vesicles, and they carried more protein, at 1107 versus 983 micrograms per milliliter. Smaller particles with denser cargo could, in principle, penetrate tumor tissue more efficiently and deliver a higher payload per unit volume.

The functional testing focused on HT-29 cells, a well-established human colorectal adenocarcinoma cell line, alongside HEK-293 human embryonic kidney cells as a normal-cell control. When treated with the plantaricin-enhanced vesicles, HT-29 cells showed a marked drop in viability as measured by the MTT assay, a colorimetric test in which metabolically active cells convert a yellow tetrazolium compound into a purple formazan product. The half-maximal inhibitory concentration, or IC50, for the enhanced vesicles was 39.10 micrograms per milliliter, significantly lower than the 52.43 micrograms per milliliter required for naive vesicles, a difference the authors report as highly significant. Crucially, neither vesicle type showed meaningful cytotoxicity toward the HEK-293 normal cells, with differences failing to reach statistical significance. That selectivity, if it holds up in more complex biological systems, is precisely the property that chemotherapy has struggled to achieve.

To confirm that the viability loss reflected genuine apoptosis rather than nonspecific toxicity, the researchers used Annexin V and propidium iodide staining followed by flow cytometry. Annexin V binds phosphatidylserine, a phospholipid that migrates from the inner to the outer leaflet of the cell membrane during the early stages of apoptosis, while propidium iodide enters only cells whose membranes have already broken down, marking late apoptosis or necrosis. The results showed a dose-dependent shift. Total apoptotic HT-29 cells rose from 6.37 percent in untreated controls to 8.37 percent after treatment with naive vesicles, and to 11.15 percent after treatment with the plantaricin-enhanced vesicles. The absolute percentages are modest, and the authors are careful to frame the effect as an apoptosis-associated response rather than a dramatic cell-killing event, but the trend was statistically robust and consistent across assays.

The molecular evidence strengthened the case considerably. Quantitative real-time polymerase chain reaction, or qRT-PCR, measured the expression of three genes that sit at the heart of the apoptotic machinery. P53, the famous guardian-of-the-genome transcription factor, was upregulated by as much as 3.5-fold in treated HT-29 cells. BAX, a pro-apoptotic member of the BCL-2 family that promotes mitochondrial outer membrane permeabilization, was similarly elevated. Meanwhile BCL-2, the anti-apoptotic counterweight that normally shields cells from self-destruction, was driven down to 0.4-fold of its baseline level. This shift in the BAX-to-BCL-2 ratio is a classic biochemical signature of cells being pushed toward the mitochondrial, or intrinsic, pathway of apoptosis. In effect, the enhanced vesicles appear to be reprogramming the cancer cells’ internal accounting so that the death signals outweigh the survival signals.

Why would preconditioning stem cells with a bacterial peptide change their vesicles so profoundly? The most plausible mechanism, though the study does not fully resolve it, is that sub-lethal plantaricin exposure activates stress-response pathways within the MSCs, altering the cargo they sort into budding vesicles. Plantaricin is known to disrupt bacterial membranes by forming pores, and mammalian cells exposed to it may respond by packaging membrane-active peptides, stress proteins, or regulatory RNAs into their extracellular vesicles. When those vesicles fuse with cancer cells, the altered cargo could tip the apoptotic balance. The smaller vesicle size observed after preconditioning may itself reflect altered membrane dynamics in stressed parent cells. Disentangling exactly which cargo molecules drive the effect will be an essential next step, and techniques such as proteomic and microRNA sequencing of the vesicle contents would help identify the active ingredients.

The broader context makes this line of research worth watching. Cell-free therapies built on extracellular vesicles are advancing rapidly across regenerative medicine and oncology, with engineered MSC-derived vesicles already being explored for targeted drug delivery in cardiac tissue and for cancer treatment more broadly. Related studies have shown that MSC microvesicles can induce apoptosis in acute myeloid leukemia cells, multiple myeloma cells, and ovarian cancer cells, and MSC-derived vesicles carrying microRNAs such as miR-15a and miR-34a-5p have been shown to suppress colorectal cancer through specific molecular axes. The present study adds a new tool to that toolbox: a simple, low-cost preconditioning step using a food-grade bacterial peptide to tune vesicle cargo toward tumor killing. Because bacteriocins are generally regarded as safe and are already consumed in fermented foods, the barrier to clinical translation of the preconditioning method itself is comparatively low.

Substantial caveats remain, and the authors acknowledge them implicitly by positioning the work as a foundation for further investigation. The experiments were conducted in two-dimensional cell culture, where drug penetration, immune clearance, and tumor heterogeneity do not exist. The modest increase in apoptotic cells, from roughly 6 to 11 percent, would need to be amplified considerably before any clinical relevance could be claimed, and the selectivity observed against HEK-293 cells must be validated against a broader panel of normal tissues. Animal studies and eventually organoid models will be needed to establish whether plantaricin-enhanced vesicles can reach colorectal tumors in vivo and accumulate at therapeutic concentrations. Still, the study demonstrates a technically sound proof of concept: that the therapeutic identity of stem cell vesicles can be rewritten by preconditioning the parent cells with a bacterial peptide, and that the resulting packages can selectively engage the apoptotic machinery of colon cancer cells. In a field hungry for treatments that are both effective and gentle, that is a result worth building on.

Subject of Research: Plantaricin-preconditioned stem cell microvesicles as a cell-free approach to inducing apoptosis in colorectal cancer cells

Article Title: Harnessing microvesicles from plantaricin-enhanced stem cells to trigger apoptosis in colon cancer cells

Article References: Yaghoubinezhad, A. R., Halabian, R., Nilchiani, L. S., & Najafi, A. (2026). Harnessing microvesicles from plantaricin-enhanced stem cells to trigger apoptosis in colon cancer cells. Molecular Biology Reports, 53(1), Article 1744. https://doi.org/10.1007/s11033-026-12922-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12922-4

Keywords: microvesicles, mesenchymal stem cells, plantaricin, colorectal cancer, apoptosis, cell-free therapy, extracellular vesicles, bacteriocins, HT-29, BAX, BCL-2, drug delivery

G0S2 is, by protein standards, remarkably minimal. It encodes a short peptide first recognized for its role at the boundary between the resting G0 phase and the proliferative G1 phase of the cell cycle, hence its name. Over the years, however, studies have tied the protein to a startling range of processes: lipid metabolism, where it binds and inhibits adipose triglyceride lipase; inflammation, where it has been linked to signaling cascades involving nuclear factor of activated T cells; and, increasingly, cell death. What has remained murky is precisely how G0S2 participates in apoptosis, particularly in the context of cancer, where tumor cells routinely suppress the very pathways that would otherwise eliminate them. The new study set out to close that gap by asking a straightforward question: what happens to the protein landscape of an organism when G0S2 is forced into overexpression?

The methodological heart of the paper is proteomics, the large-scale inventory and comparison of proteins in a biological sample. Rather than inferring what G0S2 does from gene expression alone, which can be misleading because messenger RNA levels often fail to track protein abundance, the team directly measured the protein complement of G0S2-overexpressing mice and compared it against controls. From the resulting data they performed functional annotations using Gene Ontology frameworks, pathway analysis through the Kyoto Encyclopedia of Genes and Genomes, and protein-protein interaction network mapping. These computational lenses converged on a consistent signal: among the molecular programs perturbed by G0S2 overexpression, apoptosis stood out, with multiple components of the death-signaling machinery shifting in abundance in ways consistent with an activated cell death program.

The specific players matter. BAX, or BCL2-associated X protein, is a pro-apoptotic member of the BCL-2 family that, when activated, permeabilizes the outer mitochondrial membrane, releasing factors that tip a cell into irreversible self-destruction. Caspase3 is the executioner enzyme of the pathway, a protease that once cleaved and activated systematically dismantles the cell’s structural and regulatory components. FADD, the Fas-associating protein with a novel death domain, sits at the junction of death receptor signaling, transmitting suicidal commands from the cell surface inward. Finding all three altered in G0S2-overexpressing tissue suggested that the small protein was not merely brushing against the apoptosis machinery but engaging it at multiple points, with the BAX-to-Caspase3 sequence emerging as the apparent conduit through which G0S2 exerts its effect.

Crucially, the researchers did not stop at correlation. To verify that apoptosis was genuinely occurring, they deployed TUNEL staining, a technique that flags the fragmented DNA characteristic of dying cells, alongside immunohistochemistry to visualize protein changes in tissue context, and molecular genetic strategies to interrogate the pathway’s behavior. Together, these validation experiments supported the central claim: G0S2 overexpression is associated with measurable, verifiable cell death, and the BAX/Caspase3 pathway is the mechanism through which the protein promotes it. In the language of the paper’s conclusion, G0S2 is implicated in apoptosis specifically through this axis, a finding the authors suggest could illuminate therapeutic strategies for diseases tied to apoptosis, inflammation and cancer.

The implications for hepatocellular carcinoma, the most common form of primary liver cancer, are what give the work its urgency. Hepatocellular carcinoma is a devastating malignancy, frequently diagnosed late and often arising in livers already damaged by hepatitis infection, alcohol-related injury or metabolic disease. One of the hallmarks of cancer, recognized for decades, is the ability of tumor cells to resist apoptosis, allowing damaged and genetically unstable cells to survive, proliferate and spread. If G0S2 functions as a pro-apoptotic influence, then tumors might benefit from silencing or downregulating it, and restoring its activity could, in principle, re-sensitize malignant cells to self-destruction. The authors frame the protein as a potential therapeutic target for precisely this reason, though the path from a mouse proteomics experiment to a clinical strategy is long and demanding.

It is worth situating the finding within the broader history of G0S2 research, which has been accumulating suggestive evidence for years. The protein has been reported to interact with signaling systems as varied as peroxisome proliferator-activated receptor agonists and retinoids, both of which have metabolic and differentiation-related effects on cells. It has appeared in studies of chronic kidney disease, subarachnoid hemorrhage and stress signaling, and it has been connected to networks involving mTOR, hypoxia-inducible factor 1-alpha and the DNA damage response. What the new study adds is a mechanistic anchor: a defined pathway, BAX/Caspase3, through which the protein’s apoptotic influence can be understood and, eventually, manipulated. That kind of mechanistic clarity is what transforms a protein from a statistical association in high-throughput data into a credible biological hypothesis.

The proteomic approach itself deserves attention, because it reflects a wider shift in how cancer biology is being done. Genome and transcriptome studies have catalogued countless genetic alterations in tumors, but proteins are the molecules that actually execute cellular behavior, and their regulation is layered with modifications, interactions and turnover dynamics that nucleic acid measurements cannot capture. By profiling the entire protein complement of G0S2-overexpressing tissue and then filtering the results through pathway and interaction analyses, the researchers allowed the biology to point toward its own explanation rather than testing a single preconceived candidate. The trade-off is that proteomic datasets are noisy and context-dependent, which is why the team’s follow-up validation with staining and genetic methods is essential to the study’s credibility.

Cautious optimism is the appropriate posture. The work was conducted in mice with G0S2 overexpression, and while animal models are indispensable for establishing mechanism, the translation to human hepatocellular carcinoma requires demonstrating that the protein’s expression patterns in patient tumors correlate with disease behavior, that the BAX/Caspase3 mechanism operates in human liver cancer cells, and that pharmacologically modulating G0S2 can be done safely. The liver is a metabolically central organ, and a protein implicated in lipid handling and inflammation could carry off-target consequences if simply amplified systemically. The study, supported by the National Natural Science Foundation of China and regional science programs in Shandong Province, was approved by the ethics committee of Shandong Provincial Hospital and conducted under established laboratory animal welfare guidelines, underscoring the careful preclinical framework within which such findings must be interpreted.

Even so, the study offers something that the apoptosis and liver cancer fields genuinely need: a new, compact and mechanistically grounded candidate for tipping the balance of life and death in tumor cells. The BAX/Caspase3 pathway is one of the most conserved and well-characterized death circuits in biology, and any protein that can be shown to promote its activation becomes a potential lever for intervention, whether through gene-based therapies, small molecules that stabilize the protein, or strategies that mimic its downstream effects. The authors’ stated hope is that these findings may inform novel therapeutic strategies for treating hepatocellular carcinoma, a disease for which effective options remain painfully limited. As the paper moves through the scientific conversation, the next milestones will be replication in tumor models and human tissue, and the search for ways to translate a small protein’s apoptotic push into a clinical weapon against one of the world’s most lethal cancers.

Subject of Research: The role of the G0S2 protein in regulating apoptosis via the BAX/Caspase3 pathway in hepatocellular carcinoma

Article Title: Proteomic analysis reveals G0S2 as a potential apoptosis regulator in hepatocellular carcinoma

Article References: Wu, D., Zhang, X., Qiu, Y., Sun, W., Wang, Q., Yan, Y., Jing, M., Zhang, Z., Ma, S., & Sun, M. (2026). Proteomic analysis reveals G0S2 as a potential apoptosis regulator in hepatocellular carcinoma. BMC Cancer. https://doi.org/10.1186/s12885-026-16746-0

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16746-0

Keywords: G0S2, apoptosis, hepatocellular carcinoma, proteomics, BAX, Caspase3, FADD, liver cancer, cell death, BCL-2 family, therapeutic target, stress signaling

Hepatitis B virus, a member of the Hepadnaviridae family, remains one of the leading causes of liver infection worldwide, and chronic infection can progress to hepatocellular carcinoma, one of the most lethal malignancies globally. Among the viral factors implicated in this malignant transformation, the X protein, commonly abbreviated HBx, occupies a central position. HBx is a multifunctional regulatory protein that does not directly bind DNA but instead manipulates host cell signaling pathways, transcriptional programs, and survival machinery. Decades of research have established that HBx can promote cell cycle entry, interfere with DNA repair, modulate p53-dependent responses, and tilt the balance between pro-survival and pro-death signals. Because of this pleiotropic activity, mutations accumulating in the X gene during the long course of chronic infection are thought to fine-tune the virus’s oncogenic potential, and several HBx variants have been linked epidemiologically to more aggressive liver disease.

The Indonesian team focused on the T118N substitution, in which the amino acid threonine at position 118 of HBx is replaced by asparagine. This variant had previously been detected in local clinical samples at a frequency similar to the K130M/V131I double mutant, referred to throughout the study as HBx_KV, which has been associated in multiple Asian cohorts with the development of liver carcinoma. The researchers’ earlier work had shown that the T118N mutant, designated HBx_T, actually reduced colony formation by HepG2 liver carcinoma cells, hinting that its biological effects might not simply mirror those of the better-known oncogenic mutants. To dissect what HBx_T actually does inside cells, the group designed a systematic comparison of gene expression, cell cycle distribution, and apoptotic cell death in HepG2 cells expressing either the wild-type HBx gene, the HBx_KV mutant, or the HBx_T mutant.

The experimental strategy combined three complementary readouts. First, the team used reverse transcription quantitative polymerase chain reaction, RT-qPCR, to measure the messenger RNA levels of four genes that sit at the crossroads of proliferation and apoptosis: Cyclin E, a driver of the G1-to-S phase transition; p21, a cyclin-dependent kinase inhibitor that restrains cell cycle progression; Bax, a pro-apoptotic member of the Bcl-2 family; and Bcl-2 itself, the archetypal anti-apoptotic protein. Second, they quantified cell cycle profiles by flow cytometry using propidium iodide staining, which allows the DNA content of individual cells to be measured and the proportions of cells in different cell cycle phases to be estimated. Third, they assessed apoptosis by Annexin V and propidium iodide co-staining, a standard flow cytometric approach that distinguishes early apoptotic cells, which expose phosphatidylserine on their outer membrane, from late apoptotic or necrotic cells, which lose membrane integrity altogether. As an independent confirmation of apoptotic execution, the researchers measured caspase 3 activity using a colorimetric assay kit.

The expression data revealed a clear and time-dependent pattern. At 72 hours after transfection, cells expressing the HBx_T mutant showed increased Cyclin E expression, an effect that paralleled what was observed with the HBx_KV mutant. Cyclin E drives cells through the restriction point of the G1 phase, and its upregulation is a classic hallmark of HBx-mediated proliferative signaling, so the finding places HBx_T squarely within the family of X protein variants capable of pushing hepatocytes toward DNA replication. More intriguing, however, was the behavior of the apoptotic regulators. Both Bax and Bcl-2 messenger RNA levels were elevated in HepG2 cells expressing HBx_T compared with cells expressing HBx_KV at the 72-hour time point. This simultaneous rise of a pro-apoptotic and an anti-apoptotic transcript suggests that HBx_T provokes a stronger perturbation of the Bcl-2 family rheostat, rather than a simple one-directional push toward either survival or death.

The flow cytometric apoptosis analysis sharpened this picture. At 48 hours after transfection, cells expressing HBx_T displayed increased populations of both Annexin V-positive/propidium iodide-negative cells, which represent early apoptosis, and Annexin V-positive/propidium iodide-positive cells, which represent late apoptosis or secondary necrosis, when compared with cells expressing the wild-type HBx protein. In other words, the T118N mutant appears to be a more potent inducer of apoptotic cell death than the unmutated viral protein at this time point. This observation is consistent with the team’s earlier finding that HBx_T reduces colony formation in HepG2 cells, and it aligns with a growing body of literature showing that HBx can have context-dependent, sometimes pro-apoptotic effects. Prior studies have demonstrated that HBx sensitizes hepatocytes to death receptor-mediated apoptosis through Bax, that the protein contains a BH3-like motif enabling direct interaction with Bcl-2 family members, and that persistent hepatocyte apoptosis can paradoxically promote tumorigenesis by generating oxidative stress and compensatory regenerative pressure in liver tissue.

The caspase 3 activity assay provided a biochemical anchor for these cytometric observations. Caspase 3 is the principal executioner caspase, the enzyme whose activation commits a cell irreversibly to the apoptotic program, cleaving structural proteins and dismantling the cell from within. By measuring its activity colorimetrically, the researchers could verify that the Annexin V-positive populations reflected genuine activation of the apoptotic machinery rather than artifacts of staining. Taken together with the elevated Bax transcript levels, the data support a model in which HBx_T tips the mitochondrial apoptotic pathway toward activation, even as the concurrent rise in Bcl-2 suggests a counterbalancing survival response mounted by the cells. The net outcome at any given moment in an infected liver would therefore depend on the dynamic interplay between these opposing signals, a nuance that static endpoint measurements can only partially capture.

What emerges from the study is that HBx_T influences cell cycle and apoptosis regulation through a mechanism that is similar to, but measurably distinct from, that of HBx_KV. Both mutants enhance Cyclin E expression, pointing to shared proliferative activity, but HBx_T elicits a stronger transcriptional response in the Bcl-2 family axis and a more pronounced apoptotic phenotype relative to wild-type HBx. The authors emphasize that these differences could matter for disease progression in regions where the T118N variant circulates. Chronic hepatitis B is a decades-long negotiation between virus and host, and variants that modulate the rate of hepatocyte death and proliferation can shape the inflammatory and regenerative landscape in which cancer eventually arises. Persistent apoptosis, as several studies cited by the team have shown, can fuel tumorigenesis through oxidative stress independent of compensatory liver regeneration, making an apoptosis-inducing HBx variant a candidate worth tracking in longitudinal cohort studies.

The researchers are careful to frame their conclusions as preliminary. The work was conducted in a single hepatoblastoma-derived cell line, HepG2, using transient transfection rather than authentic viral infection, and the measurements capture snapshots at 48 and 72 hours rather than the protracted timescales relevant to human chronic infection. The authors state explicitly that further investigations are still required to understand the involvement of the HBx_T mutant in the development of chronic liver disease and liver cirrhosis. Future work will likely need to address how the T118N substitution alters the protein’s structure and its interactions with host factors, whether the same phenotypes appear in primary hepatocytes or in vivo models, and how HBx_T behaves in combination with other common HBV mutations, such as those in the basal core promoter or precore regions, that frequently co-occur in patients with advanced disease.

Nevertheless, the study adds a meaningful piece to the puzzle of HBV-associated carcinogenesis. By showing that a naturally circulating Indonesian HBx variant modulates the Cyclin E, p21, Bax, and Bcl-2 network in a distinguishable way from the canonical K130M/V131I mutant, the Bandung team underscores a broader principle in viral oncology: the oncogenic potential of hepatitis B virus is not a fixed property of the virus but a moving target shaped by the mutations that accumulate in individual patients. Mapping the functional spectrum of these variants, particularly those prevalent in under-studied regions and genotypes, could ultimately improve risk stratification for hepatocellular carcinoma and inform surveillance strategies for the hundreds of millions of people living with chronic hepatitis B worldwide.

Subject of Research: Effect of the hepatitis B virus X protein T118N mutation on cell cycle and apoptosis regulation in HepG2 liver cells

Article Title: Effect of Hepatitis B virus X T118N mutant protein in HepG2 cell cycle and apoptosis regulation

Article References: Artarini, A., Seniadi, K., Mahaputra, A. R. G., Ridwani, D. S. K., & Prasetyo, V. N. A. (2026). Effect of Hepatitis B virus X T118N mutant protein in HepG2 cell cycle and apoptosis regulation. Molecular Biology Reports, 53(1), Article 1708. https://doi.org/10.1007/s11033-026-12923-3

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12923-3

Keywords: hepatitis B virus, HBx, T118N mutation, HepG2 cells, cell cycle, apoptosis, Cyclin E, Bax, Bcl-2, hepatocellular carcinoma, flow cytometry, RT-qPCR

5-fluorouracil, often abbreviated 5-Fu, has been a cornerstone of colorectal cancer treatment for decades. It works by interfering with DNA synthesis, forcing rapidly dividing cells to self-destruct. Yet its clinical performance remains constrained by two persistent problems: limited efficacy in many patients and a spectrum of serious side effects that can force dose reductions or treatment interruptions. These limitations have driven an intensive search for compounds that could sensitize tumors to 5-Fu, allowing lower doses to achieve the same or better effect. The new study positions a bacterial fermentation product as a candidate for exactly that role.

The research team, led by scientists at the Research Institute for Gastroenterology and Liver Diseases at Shahid Beheshti University of Medical Sciences in Tehran, took a systematic approach to comparing three different preparations of L. reuteri, a strain catalogued as IBRC-M 10755. They tested live bacteria, heat-killed bacteria, and the cell-free supernatant, the liquid fraction left behind after the bacteria are removed, which contains the bacterium’s secreted metabolites, proteins, and other molecules. Each preparation was applied to SW-480 cells, a well-established laboratory model of colorectal cancer, both alone and in combination with 5-fluorouracil across concentrations ranging from 1 to 100 micromolar, over 24 to 48 hours.

The results revealed a striking hierarchy among the three preparations. Live L. reuteri, tested at multiplicities of infection of 1, 10, and 100, had no effect on cancer cell viability at any concentration. Heat-killed bacteria at the highest multiplicity of infection, 100, reduced viability by up to 85 percent. The cell-free supernatant, tested at total protein concentrations of 1, 10, 25, and 50 micrograms per milliliter, cut viability by up to 78 percent at 25 micrograms per milliliter and 65 percent at 50 micrograms per milliliter, with statistical significance relative to untreated cells. The pattern suggests that whatever anticancer activity the bacterium possesses resides largely in what it secretes rather than in the living organism itself.

To understand how the supernatant killed the cancer cells, the researchers turned to the molecular machinery of apoptosis. Using quantitative real-time PCR, they measured the expression of five genes that act as regulators and executors of programmed cell death: Bax, a pro-apoptotic member of the Bcl-2 family; Bcl-2, its anti-apoptotic counterpart; and the initiator and executioner caspases 8, 9, and 3. Treatment with live bacteria, heat-killed bacteria at the highest dose, and the supernatant at 25 to 50 micrograms per milliliter all significantly increased the expression of Bax, caspase-3, caspase-8, and caspase-9. The simultaneous engagement of both the extrinsic pathway, signaled through caspase-8, and the intrinsic pathway, signaled through caspase-9, points to a broad activation of the cell’s suicide program rather than a single narrow trigger.

Flow cytometry provided independent confirmation. Cells stained with fluorescent markers that distinguish early apoptotic cells from late apoptotic and necrotic ones showed a dose-dependent increase in apoptosis following supernatant treatment, rising in step with the concentration of total protein applied. This dose-response relationship is an important technical detail, because it indicates a genuine pharmacological effect rather than random toxicity. It also aligns the gene expression data with the functional outcome: cells exposed to higher concentrations of the bacterial supernatant not only talked the apoptotic talk at the RNA level but actually walked the walk, dying at measurably higher rates.

The most clinically intriguing result emerged when the supernatant was combined with 5-fluorouracil. Co-treatment with the cell-free supernatant and a relatively low 10 micromolar dose of the drug produced greater expression of apoptosis-related genes and a higher apoptosis rate than either agent achieved alone. In practical terms, the bacterial metabolites appeared to lower the threshold at which the cancer cells capitulated to the chemotherapy. If this synergy could be reproduced in a living tumor, it might eventually allow oncologists to achieve therapeutic effects with reduced 5-Fu exposure, potentially sparing patients some of the drug’s harsh side effects, which include bone marrow suppression and gastrointestinal toxicity.

The study also examined the inflammatory dimension of the interaction. 5-fluorouracil is known to provoke inflammatory signaling, and chronic inflammation in the tumor microenvironment can undermine treatment. When SW-480 cells received the combined treatment, the drug-induced elevation of messenger RNA for two key inflammatory cytokines, tumor necrosis factor alpha and interleukin-1 beta, was significantly blunted. However, the researchers noted an important caveat: when they measured the actual secreted protein levels of these cytokines by enzyme-linked immunosorbent assay, the reduction was not consistently reflected. This discordance between mRNA and protein levels is a familiar challenge in molecular biology and underscores that transcriptional changes do not always translate cleanly into changes in secreted signaling molecules.

The authors are careful to frame their findings as preliminary. Because the work was conducted entirely in vitro, on a single cell line in culture dishes, it cannot speak to how the supernatant would behave in the far more complex environment of a human tumor, where immune cells, blood supply, and drug metabolism all intervene. The researchers explicitly call for formal combination-index analysis, a mathematical framework for quantifying whether two agents are truly synergistic, additive, or antagonistic, as well as for validation in animal models before any therapeutic claims can be made. The study was funded by the Iran National Science Foundation and the Research Institute for Gastroenterology and Liver Diseases, and the authors declare no competing interests.

Even with those caveats, the study contributes a well-characterized data point to an increasingly active field exploring how probiotic derivatives might complement cancer chemotherapy. The observation that the cell-free supernatant outperformed both live and heat-killed bacteria is particularly noteworthy, because a cell-free preparation would avoid the safety concerns associated with administering live microorganisms to immunocompromised cancer patients. If subsequent work identifies the specific molecules in the L. reuteri supernatant responsible for sensitizing SW-480 cells to 5-fluorouracil, the door could open to standardized, purified adjunct therapies built from the chemistry of the gut microbiome. For now, the message is one of cautious optimism: a familiar probiotic’s secretions, in a petri dish at least, appear to help a fifty-year-old chemotherapy drug finish the job it was designed to do.

Subject of Research: Probiotic-derived cell-free supernatant as an adjunct to 5-fluorouracil chemotherapy in colorectal cancer cells

Article Title: Cell-free supernatant of Limosilactobacillus reuteri enhances 5-fluorouracil-induced apoptosis in SW-480 colorectal cancer cells: an in vitro study

Article References: Saeedi Niasar, M., Sadeghi, A., Tarzemani, S., Safarpour, H., Alipour, S., Ghazvinian, Z., Yazdani, E., & Raeisi, H. (2026). Cell-free supernatant of Limosilactobacillus reuteri enhances 5-fluorouracil-induced apoptosis in SW-480 colorectal cancer cells: an in vitro study. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05611-z

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05611-z

Keywords: Limosilactobacillus reuteri, 5-fluorouracil, colorectal cancer, apoptosis, cell-free supernatant, probiotics, SW-480 cells, chemotherapy, caspases, Bax, Bcl-2, in vitro study

The new work, published in Nature Chemical Biology, tackles a problem that has frustrated the apoptosis field since BAX was first implicated in ischemic injury: the protein is a moving target. In healthy cells, BAX lounges in the cytosol as an inactive monomer, its lethal membrane-penetrating helices tucked away inside its own structure. Only when death signals accumulate does BAX undergo a dramatic conformational transformation, exposing its N-terminus, unfurling its ninth alpha helix, and migrating to the mitochondrial outer membrane, where it oligomerizes into pores. Small molecules that bind the resting state have been described before, but they tend to be weak, poorly characterized, or reactive with many unrelated proteins, making them unreliable tools and even less reliable medicines.

The team behind the new study took a different approach: rather than hunting for a generic binder, they engineered a covalent warhead aimed at a specific cysteine residue on the surface of inactive BAX. Covalent inhibitors have enjoyed a renaissance in recent years, most famously in the form of acrylamide-based drugs that target a non-catalytic cysteine in EGFR-mutant lung cancer. The strategy offers the allure of prolonged target engagement at low drug concentrations, but it carries a well-known risk: off-target reactivity with the many cysteine-rich proteins floating in any cell. The challenge, therefore, was to design a ligand whose reactivity is only unleashed in the precise geometric context of the BAX binding pocket.

That is where the concept of enantioselectivity becomes central. Small drug-like molecules typically exist as two enantiomers, mirror-image forms that are chemically identical in an achiral test tube but profoundly different in the chiral environment of a living cell. Enzymes, receptors, and protein binding pockets distinguish between these mirror images with exquisite sensitivity, often binding one form tightly while ignoring the other. The researchers exploited this principle twice over: first by synthesizing both enantiomers of their candidate inhibitor and then by demonstrating that only one of them engages BAX efficiently, while the opposite enantiomer is essentially inert. This one-handed specificity is a hallmark of a well-behaved chemical probe and stands in sharp contrast to earlier BAX inhibitors whose activity could not be cleanly separated from nonspecific protein damage.

The design process began with structural analysis of the inactive BAX monomer, using prior nuclear magnetic resonance structures and molecular docking to identify a pocket adjacent to a reactive cysteine. The team then iterated through a series of analogues, tuning the electrophilic warhead and the surrounding scaffold until they achieved a compound that reacts with BAX rapidly and selectively in competition assays against a broad panel of cysteine-containing proteins. Chemoproteomic experiments in cell lysates confirmed the selectivity on a proteome-wide scale, showing that the compound’s covalent footprint is dominated by BAX rather than by the hundreds of other cysteine residues available for reaction. This kind of global reactivity profiling has become the gold standard for validating covalent chemistry, and its successful application here lends substantial credibility to the probe.

With a selective inhibitor in hand, the researchers turned to functional testing. In cell culture, the compound protected cells from apoptotic death provoked by a variety of stresses, and the protection was abolished when BAX was removed or when a non-reactive analogue was substituted, establishing that the cytoprotective effect runs through the intended target. Biochemical assays showed that the covalently modified BAX can no longer expose its membrane-inserting helix or translocate to mitochondria in response to activating signals, effectively locking the protein in its harmless resting conformation. The modification also prevented BAX oligomerization, the downstream step that converts individual protein molecules into the pore-forming assemblies that rupture the mitochondrial membrane and release cytochrome c.

The most consequential experiments, however, were performed in living animals. In a mouse model of ischemia-reperfusion injury, a scenario that mirrors the cellular damage that follows a heart attack or stroke, administration of the active enantiomer significantly reduced tissue damage compared with vehicle controls. Critically, the mirror-image enantiomer, which lacks BAX reactivity in vitro, provided no protection, a rigorous in vivo control that ties the therapeutic benefit directly to the covalent engagement of BAX. Pharmacokinetic measurements confirmed that the compound reaches relevant tissues at concentrations sufficient to modify the target, and the treated animals tolerated the drug without overt toxicity, an encouraging early signal for a strategy that modifies a protein involved in fundamental cellular quality control.

Experts in the apoptosis field have long debated whether inhibiting BAX systemically is safe or even desirable, given the protein’s role in eliminating damaged or potentially cancerous cells. The new study does not resolve that debate, but it sharpens the terms of the discussion. Because the inhibitor is covalent and long-acting, dosing regimens could in principle be tailored to acute, short-term scenarios, such as the hours surrounding reperfusion therapy after a myocardial infarction, where transient BAX inhibition might salvage tissue without the long-term cancer risks that chronic suppression might entail. The authors’ demonstration that a single enantiomer drives the entire pharmacological effect also suggests that medicinal chemistry optimization can proceed with confidence, since the inactive mirror image provides a built-in negative control for every future experiment.

The work also carries broader lessons for chemical biology. Covalent inhibitors were once viewed as liabilities to be engineered out of drug candidates; today they are a deliberate design choice, provided that selectivity is demonstrated rigorously. The BAX program illustrates the full pipeline: structural insight to identify a ligandable site, warhead tuning to balance reactivity and selectivity, enantiomer pairing to isolate specific from nonspecific effects, chemoproteomics to survey the proteome, and animal models to test whether the molecular mechanism translates into tissue-level protection. Each step reinforces the others, and the resulting probe is far more than a tool; it is a proof of concept that a notoriously difficult, conformationally dynamic protein can be drugged with precision.

Looking ahead, the researchers and their colleagues face the familiar gauntlet of translation: optimizing potency and pharmacokinetics, assessing safety across longer time horizons, and identifying the clinical settings where BAX inhibition offers the greatest benefit at the least risk. Beyond ischemic injury, candidates include neurodegenerative conditions in which mitochondrial apoptosis contributes to neuronal loss, and organ transplantation, where protecting donor tissue from programmed death could extend viability and improve outcomes. Whatever the ultimate therapeutic destination, the demonstration that an enantioselective covalent inhibitor of BAX can confer cytoprotection in vivo marks a milestone in the long campaign to control the machinery of cell death, and it hands the field a chemical instrument of unprecedented specificity for dissecting BAX biology in health and disease.

Subject of Research: Development of an enantioselective covalent small-molecule inhibitor of the pro-apoptotic protein BAX that prevents mitochondrial apoptosis and provides cytoprotection in vivo.

Article Title: An enantioselective covalent inhibitor of BAX confers cytoprotection in vivo

Article References: Shi, P., Melillo, B., McHenry, M. W., Camara, C. M., Yang, K., Njomen, E., Godes, M., Pazyra-Murphy, M. F., Branch, M. R., Tesar, B., Segal, R. A., Rubin, L. L., Cameron, M. D., Bird, G. H., Wales, T. E., Gygi, S. P., Cravatt, B. F., & Walensky, L. D. (2026). An enantioselective covalent inhibitor of BAX confers cytoprotection in vivo. Nature Chemical Biology. https://doi.org/10.1038/s41589-026-02297-9

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02297-9

Keywords: BAX, apoptosis, covalent inhibitor, enantioselectivity, mitochondria, cytoprotection, ischemia-reperfusion injury, chemical biology, drug design, chemoproteomics, Nature Chemical Biology, cell death